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Abstract
The aim of this commentary is to summarize some of the recent articles on biology of 
human lactate dehydrogenase A (hLDH-A) in normal and cancer cells that support the 
anticancer therapeutic approach based on hLDH-5 inhibition. Up till now, no suitable 
drug is known that selectively inhibits hLDH-A and can be used for tumor therapies in 
the clinics throughout the world. This review thus encourages the academic institutions 
and pharmaceutical industries in search of specifi c inhibitors for hLDH-A.
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Introduction and Discussion
It is known that most of the energy in the form of adenosine 
triphosphate (ATP) required for cellular functions is released 
from dietary molecules (glucose, fatty acids, and amino acids) 
is by oxidative (aerobic) metabolism.[1] However, when there is 
hypoxia, energy released from glucose (and glycogen) is shifted 
to anaerobic pathway where pyruvate of glycolysis is converted 
into lactic acid.[1,2] In this pathway, overall although the energy 
production is quite less than aerobic metabolism but due to 
regeneration of nicotinamide adenine dinucleotide (NAD+), 
the anaerobic glycolysis continue for a long time without 
oxygen.[3] In this way, the cells continue to obtain energy, 
although less but “something is better than nothing” and is a 
temporary compensatory mechanism. In the case of cancer 
cells, although there is no hypoxia in the body but probably 
due to microhypoxia (the so-called diﬀ usion-limited hypoxia) 
in specifi c tumor tissues, cells prefer anaerobic glycolysis 
for energy production.[2,4] This is called as Warburg eﬀ ect as 
suggested by the Warburg[5] and catalyzed by an enzyme known 
as lactate dehydrogenase (LDH; EC 1.1.1.27).[6] This is a 
tetrameric enzyme made up of two diﬀ erent protein subunits 
(LDH-A or LDH-M or LDH-5 and LDH-B or LDH-H or 
LDH-1), each one is encoded by separate genes. Here, LDH-M 
isoenzyme means that mostly synthesized in skeletal muscle 
and LDH-H means that mostly synthesized in heart muscle. 
This enzyme is necessary for interconversion of pyruvate, and 
NAD hydrogen (NADH) generated during glycolysis to lactate 
and NAD+, respectively, (for details read reviews written by 
Ahmed and Dingding[7] and Valvona et al.[8]). The isoenzyme-A 
favors the formation of lactate from pyruvate (anaerobic 
metabolism) and the isoenzyme-B favors the reverse reaction 
(aerobic metabolism).[9] The direction of catalytic reaction 
depends on the proportion of LDH-A and LDH-B isoenzymes 
in the LDH complex. It is proposed that the uptake of pyruvate 
by mitochondria is suppressed during anaerobic metabolism. 
This pyruvate is then converted to lactate by cytosolic LDH-A 
isoenzyme and thus reduces the growing pyruvate pool and 
thereby regenerating NAD+ that allows energy production to 
continue, especially in cancer cells/tissues. The regenerated 
NAD+ is required to use more and more glucose/glycogen for 
anaerobic glycolysis to produce enough ATP for the survival of 
cells. Thus, LDH-A is the main regulatory enzyme involved in 
sustaining cancer’s glycolytic energy and phenotype[7,10] as most 
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of the tumor cells are reliant on lactate production for their 
survival.[11]
Therefore, it has been suggested that human LDH-A 
(hLDH-A) could be a good molecular target for the drugs that 
can thus inhibit the anaerobic glycolysis. Thus, this specifi c 
inhibition then could be a good step to inhibit the growth 
and proliferation of cancer cells.[7] Some researchers have 
already reported the inhibition of hLDH-A by small molecules 
that showed antiproliferative activity.[7,12,13] Another related 
observation has also supported this view. In that, when there is 
a complete genetic defi ciency of LDH-A isoenzyme, there are 
no observed signs and symptoms of cancer in those humans 
under normal circumstances.[14,15] Recently, it has been shown 
by Allison et al.[10] that knockdown of the LDH-A by RNA 
interference (RNAi) results in death of HCT116 cancer cells. 
Similarly by upregulation of LDH-A isoenzyme, some studies 
indicated that proliferation of tumor cells in enhanced. This 
was particularly seen in those cancers that have high malignant 
potential.[7,16] According to Zhou et al.,[17] the breast cancer cells 
become resistant to taxol and in these patients the hLDH-A 
was shown to be elevated. They also observed that these taxol-
resistant cells are quite sensitive to inhibitory eﬀ ect of oxamate 
(an analog of pyruvate). The upregulation of LDH-A gene in 
cancer cells by oncogenic signals (such as hypoxia-inducible 
factor [HIF] and Myc) is believed to be due to phosphorylation 
of LDH-A via the oncogenic receptor tyrosine kinase.[11] It has 
been shown by Fan et al.[11] that phosphorylation at Y10 and 
Y83 potentiates LDH-A activity by many folds. The promotion, 
cancer cell metabolism and tumor growth is then achieved by 
the regulation of NADH/NAD+ ratio. This represents an acute 
molecular mechanism underlying lactate production and the 
Warburg eﬀ ect, while the chronic mechanism is thought to be 
regulated by Myc and HIF.[11] When the LDH-A was down-
regulated by specifi c hLDH-A RNAi, LDH-A activity was also 
decreased in the cells and these cells then become more sensitivity 
to the treatment of taxol (re-sensitization mechanism).
However, LDH-A inhibition does not only inhibit anaerobic 
glycolysis but also alters the balance between NAD+/NADH 
ratio in the cells. This could disturb the homeostasis of other 
cellular processes and enzymes dependent on the ratio of NAD+/
NADH. Some of these enzymes have critical physiological and 
therapeutic functions. An example for this is the oxidoreductase 
NAD(P)H quinone oxidoreductase 1 that uses NADH to reduce 
the quinone-based anticancer prodrug Apaziquone (EO9) to 
cytotoxic metabolites.[18]
These fi ndings and observations suggest that selective 
hLDH-A inhibitors could be very useful in the treatment of 
cancer.[7,19] However, the ratio of NAD+/NADH is also required 
for functions of normal (noncancer) cells, and this approach 
carries a risk of toxicity to normal cells.[20] Thus, strategies 
designed to modulate NAD+/NADH ratio selectively in cancer 
cells are required, and one potential approach is targeting 
hLDH-A in cancer cells. Therefore, hLDH-A is considered 
an attractive molecular target for the development of novel 
anticancer agents.[7]
Conclusion
According to Valvona et al.,[8] “currently there is no suitable 
hLDH-A inhibitors available for tumor therapies in the clinic.” 
Thus, it is concluded that although many research institutions 
including some Pharma companies are involved in this task, 
the discovery of specifi c hLDH inhibitors that can be used 
as drugs looks very diﬃ  cult to resolve this scientifi c burning 
challenge.
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